Ligand Pharmaceuticals Incorporated
LGND
$104.97
$0.350.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -31.09M | -7.17M | -51.91M | 86.14M | 18.19M |
| Total Depreciation and Amortization | 8.63M | 8.99M | 8.85M | 8.77M | 8.92M |
| Total Amortization of Deferred Charges | 743.00K | 707.00K | 600.00K | 562.00K | 585.00K |
| Total Other Non-Cash Items | 38.59M | 26.88M | 63.38M | -84.98M | -3.63M |
| Change in Net Operating Assets | 11.60M | 7.12M | -7.61M | 8.24M | -15.99M |
| Cash from Operations | 28.47M | 36.53M | 13.31M | 18.73M | 8.07M |
| Capital Expenditure | -712.00K | -596.00K | -408.00K | -105.00K | -417.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -37.91M | -45.91M | -54.35M | -3.67M | -9.87M |
| Cash from Investing | -38.62M | -46.51M | -54.76M | -3.78M | -10.28M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -6.00K | -10.00K | -4.00K | -5.00K | -5.00K |
| Issuance of Common Stock | 56.48M | 21.40M | 9.55M | 15.30M | 6.53M |
| Repurchase of Common Stock | -1.94M | -125.00K | 0.00 | -3.08M | -257.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -34.15M | 33.82M | -57.00K | -41.00K | -949.00K |
| Cash from Financing | 20.39M | 55.08M | 9.49M | 12.18M | 5.32M |
| Foreign Exchange rate Adjustments | -1.55M | 377.00K | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.69M | 45.48M | -31.95M | 27.14M | 3.10M |